NO20082923L - Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni - Google Patents

Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni

Info

Publication number
NO20082923L
NO20082923L NO20082923A NO20082923A NO20082923L NO 20082923 L NO20082923 L NO 20082923L NO 20082923 A NO20082923 A NO 20082923A NO 20082923 A NO20082923 A NO 20082923A NO 20082923 L NO20082923 L NO 20082923L
Authority
NO
Norway
Prior art keywords
schizophrenia
negative symptoms
antagonist
side effects
combination
Prior art date
Application number
NO20082923A
Other languages
English (en)
Inventor
Mark Black
Beth Borowsky
Nancy Rogacki
Yaw Senyah
Rachel Stevens
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20082923L publication Critical patent/NO20082923L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse beskriver en fremgangsmåte for behandling av kognisjonsunderskudd hos en pasient som lider av schizofreni ved administrering til nevnte pasient en terapeutisk effektiv mengde av en CB1-reseptorantagonist slik det er beskrevet heri. I et annet aspekt, angår oppfinnelsen også en kombinasjon av en eller flere CBlreseptorantagonister og et eller flere antipsykotiske midler anvendelige ved behandling av psykiatriske forstyrrelser. Kombinasjonen ifølge oppfinnelsen tilveiebringer synergistiske resultater i at kombinasjonen forbedrer positive og negative symptomer på schizofreni, vekstøkning og katalepsi.
NO20082923A 2005-12-08 2008-06-25 Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni NO20082923L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74843405P 2005-12-08 2005-12-08
PCT/US2006/046547 WO2007067617A2 (en) 2005-12-08 2006-12-07 Use of a cb1 antagonist for treating negative symptoms of schizophrenia

Publications (1)

Publication Number Publication Date
NO20082923L true NO20082923L (no) 2008-09-02

Family

ID=37964962

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082923A NO20082923L (no) 2005-12-08 2008-06-25 Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni

Country Status (23)

Country Link
US (1) US20080221078A1 (no)
EP (1) EP1962834A2 (no)
JP (1) JP2009518423A (no)
KR (1) KR20080073737A (no)
CN (1) CN101321523A (no)
AR (1) AR056846A1 (no)
AU (1) AU2006321907A1 (no)
BR (1) BRPI0619541A2 (no)
CA (1) CA2632673A1 (no)
CR (1) CR9957A (no)
DO (1) DOP2006000273A (no)
EC (1) ECSP088505A (no)
IL (1) IL191888A0 (no)
MA (1) MA30090B1 (no)
NO (1) NO20082923L (no)
PE (1) PE20071092A1 (no)
RU (1) RU2008127491A (no)
SV (1) SV2008002929A (no)
TN (1) TNSN08205A1 (no)
TW (1) TW200803839A (no)
UY (1) UY29995A1 (no)
WO (1) WO2007067617A2 (no)
ZA (1) ZA200803924B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
JP2010540629A (ja) * 2007-10-04 2010-12-24 メルク・シャープ・エンド・ドーム・コーポレイション カルシウムチャネル遮断薬としての置換アリールスルホン誘導体
FR2925051B1 (fr) * 2007-12-18 2010-05-21 Sanofi Aventis Derives d'azetidines,leur preparation et leur application en therapeutique
EA019315B1 (ru) * 2007-12-18 2014-02-28 Санофи-Авентис Производные азетидинов, их получение и применение в терапии
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
HUE055262T2 (hu) 2014-08-11 2021-11-29 Angion Biomedica Corp Citokróm P450 inhibitorok és ezek alkalmazásai
AU2015374231B2 (en) 2014-12-31 2020-07-23 Angion Biomedica Corp. Methods and agents for treating disease
JP6912574B2 (ja) 2016-08-24 2021-08-04 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
US7485732B2 (en) * 2003-06-11 2009-02-03 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
EP1663215A1 (en) * 2003-09-02 2006-06-07 Solvay Pharmaceuticals GmbH Novel medical use of selective cb1- receptor antagonists
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
FR2882931B1 (fr) * 2005-03-14 2007-05-18 Sanofi Aventis Sa Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique

Also Published As

Publication number Publication date
CN101321523A (zh) 2008-12-10
MA30090B1 (fr) 2008-12-01
CA2632673A1 (en) 2007-06-14
AR056846A1 (es) 2007-10-24
KR20080073737A (ko) 2008-08-11
IL191888A0 (en) 2009-08-03
TNSN08205A1 (en) 2009-10-30
ECSP088505A (es) 2008-08-29
ZA200803924B (en) 2009-10-28
SV2008002929A (es) 2009-12-02
BRPI0619541A2 (pt) 2011-10-04
AU2006321907A1 (en) 2007-06-14
WO2007067617A3 (en) 2007-11-01
DOP2006000273A (es) 2007-10-15
UY29995A1 (es) 2007-07-31
US20080221078A1 (en) 2008-09-11
CR9957A (es) 2008-09-22
TW200803839A (en) 2008-01-16
WO2007067617A2 (en) 2007-06-14
PE20071092A1 (es) 2007-12-10
EP1962834A2 (en) 2008-09-03
JP2009518423A (ja) 2009-05-07
RU2008127491A (ru) 2010-01-20

Similar Documents

Publication Publication Date Title
NO20082923L (no) Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
HRP20130345T1 (hr) NOVI TERAPIJSKI PRISTUPI ZA LIJEČENJE CMT-a I SRODNIH POREMEĆA
TNSN07376A1 (en) Npy antagonists, preparation and use
EA201200686A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера
BRPI0506970B8 (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
WO2005103041A3 (en) Treatment of cns disorders using cns target modulators
CL2010001173A1 (es) Compuestos derivados de 1,4-diazepam sustituido, antagonistas de ox1 y ox2; utiles para preparar un medicamento destinado al tratamiento o prevencion de un trastorno del sueño,para potenciar la calidad del sueno,y para tratar o controlar la obesidad.(divisional de la sol.n 3441-07)
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
MY161656A (en) Therapeutic use of diaminophenothiazines
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
NO20063856L (no) Behandling av psykoser med quetiapin-antipsykotiske midler
WO2009036996A3 (en) Small molecule bradykinin b1 receptor antagonists
MX2011010782A (es) Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.
NO20083838L (no) Anvendelse av KCNQ-apnere for a behandle eller redusere symptomene pa schizofreni
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
MX2009001315A (es) Compuestos de dimetilciclobutilo substituidos, su preparación y uso en medicamentos.
WO2007005940A3 (en) Combinations of eszopiclone and didesmethylsibutramine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
WO2007100430A3 (en) Cytisine and acetylcholine analogs and methods of treating mood disorders
ZA200609220B (en) Method of treating dry eye disorders and uveitis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application